Emend 150mg Injection

About

Fosaprepitant is an intravenous prodrug of aprepitant, a highly selective neurokinin-1 (NK1) receptor antagonist. Upon administration, it is rapidly converted to its active metabolite, aprepitant, in vivo. Aprepitant then exerts its antiemetic effect by blocking the binding of substance P, a key neuropeptide, to the NK1 receptor in the central nervous system, particularly in the area postrema. This action effectively prevents both the acute and, importantly, the delayed phases of chemotherapy-induced nausea and vomiting (CINV). Fosaprepitant is typically administered as a single dose prior to chemotherapy and is used in combination with other antiemetic agents, such as corticosteroids (e.g., dexamethasone) and 5-HT3 receptor antagonists (e.g., ondansetron), to provide comprehensive and enhanced control of emesis in patients receiving highly or moderately emetogenic chemotherapy, offering a convenient intravenous option.

Uses

• Prevention of acute chemotherapy-induced nausea and vomiting.
• Prevention of delayed chemotherapy-induced nausea and vomiting.
• Used in combination with other antiemetics for highly emetogenic chemotherapy.
• Used in combination with other antiemetics for moderately emetogenic chemotherapy.

Directions For Use

Administer as an intravenous infusion over 20-30 minutes, as directed by your healthcare provider, prior to chemotherapy.

Benefits

• Highly effective in preventing chemotherapy-induced nausea.
• Significantly reduces chemotherapy-induced vomiting.
• Covers both acute and delayed phases of CINV.
• Convenient single-dose intravenous administration.
• Enhances the efficacy of other antiemetic drugs.
• Improves patient comfort and adherence to chemotherapy.

Side Effects

• Fatigue
• Dizziness
• Headache
• Hiccups
• Constipation
• Diarrhea
• Injection site reactions
• Anorexia
• Neutropenia
• Increased liver enzymes
• Hypotension
• Bradycardia

Safety Measures

• Alcohol - No specific contraindication, but general health advice regarding alcohol consumption should be followed.
• Pregnancy - Use only if clearly needed and potential benefits outweigh risks; consult a doctor.
• Breastfeeding - Caution is advised; it is unknown if fosaprepitant or its metabolite aprepitant is excreted in human milk.
• Liver - Use with caution in severe liver impairment; monitor patients closely.
• Kidney - No specific dose adjustment required for kidney impairment.
• Lung - Generally safe for use in patients with lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.